

# Carmine Dario Vizza

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4090751/carmine-dario-vizza-publications-by-year.pdf>

**Version:** 2022-10-05

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

155  
papers

8,056  
citations

37  
h-index

89  
g-index

189  
ext. papers

9,767  
ext. citations

5.4  
avg, IF

5.21  
L-index

#	Paper	IF	Citations
155	Future perspective in diabetic patients with pre- and post-capillary pulmonary hypertension.. <i>Heart Failure Reviews</i> , <b>2022</b> , 1	4.8	
154	Complex connections: A young man presenting with shortness of breath, hypoxemia, right lumbar pain and left limb swelling.. <i>Echocardiography</i> , <b>2022</b> ,	1.4	
153	ECMO Assistance during Mechanical Ventilation: Effects Induced on Energetic and Haemodynamic Variables. <i>Computer Methods and Programs in Biomedicine</i> , <b>2021</b> , 202, 106003	6.6	2
152	Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , <b>2021</b> , 9, 573-584	33.9	16
151	Right ventricular assessment matters for precision medicine. Reply to "Identifying parameters associated with response to switching from a PDE5i to riociguat in RESPITE". <i>International Journal of Cardiology</i> , <b>2021</b> , 333, 210	3	
150	Incidence and long-term outcomes of pregnant women complicated with pulmonary arterial hypertension during different pregnancies: A prospective cohort study from China. <i>International Journal of Cardiology</i> , <b>2021</b> , 332, 193-194	3	
149	Reply to Weatherald : Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension: La PiÙe de Rĳistance?. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> , 203, 525-526	9.6	
148	Right Ventricular Strain Curve Morphology and Outcome in Idiopathic Pulmonary Arterial Hypertension. <i>JACC: Cardiovascular Imaging</i> , <b>2021</b> , 14, 162-172	8	7
147	Risk Reduction and Hemodynamics with Initial Combination Therapy in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> , 203, 484-492	9.6	11
146	Right-Heart Reverse Remodeling During Treatment for Pulmonary Hypertension <b>2021</b> , 291-299		
145	The Growing Role of Echocardiography in Pulmonary Arterial Hypertension Risk Stratification: The Missing Piece. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	4.9	6
144	The Authors Reply. <i>JACC: Cardiovascular Imaging</i> , <b>2021</b> , 14, 1488-1489	8	
143	Pulmonary Hypertension in Patients With COPD: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). <i>Chest</i> , <b>2021</b> , 160, 678-689 <sup>1,2</sup>		11
142	Medical treatment of pulmonary hypertension in adults with congenital heart disease: updated and extended results from the International COMPERA-CHD Registry.. <i>Cardiovascular Diagnosis and Therapy</i> , <b>2021</b> , 11, 1255-1268	2.4	
141	Aggressive Afterload Lowering to Improve the RV: A New Target for Medical Therapy in PAH?. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> ,	9.6	1
140	Temporal trends in pulmonary arterial hypertension: Results from the COMPERA registry. <i>European Respiratory Journal</i> , <b>2021</b> ,	13.1	3
139	COMPERA 2.0: A refined 4-strata risk assessment model for pulmonary arterial hypertension. <i>European Respiratory Journal</i> , <b>2021</b> ,	13.1	4

138	Risk Reduction and Right Heart Reverse Remodeling by Upfront Triple Combination Therapy in Pulmonary Arterial Hypertension. <i>Chest</i> , <b>2020</b> , 157, 376-383	1.2	31
137	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). <i>European Heart Journal</i> , <b>2020</b> , 41, 543-603 <sup>9</sup>		922
136	Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	4.9	8
135	Intra-aortic balloon counterpulsation timing: A new numerical model for programming and training in the clinical environment. <i>Computer Methods and Programs in Biomedicine</i> , <b>2020</b> , 194, 105537	6.6	1
134	Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension. <i>Arthritis Research and Therapy</i> , <b>2020</b> , 22, 127	5.5	6
133	Usefulness of Adding Echocardiography of the Right Heart to Risk-Assessment Scores in Prostanoid-Treated Pulmonary Arterial Hypertension. <i>JACC: Cardiovascular Imaging</i> , <b>2020</b> , 13, 2054-2056 <sup>8</sup>		5
132	Clinical implications of idiopathic pulmonary arterial hypertension phenotypes defined by cluster analysis. <i>Journal of Heart and Lung Transplantation</i> , <b>2020</b> , 39, 310-320	1	12
131	The importance of right ventricular evaluation in risk assessment and therapeutic strategies: Raising the bar in pulmonary arterial hypertension. <i>International Journal of Cardiology</i> , <b>2020</b> , 301, 183-189 <sup>2</sup>		22
130	Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2020</b> , 201, 707-717	9.6	37
129	Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentan-tadalafil in pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , <b>2020</b> , 39, 1389-1397	1	3
128	Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. <i>Journal of Heart and Lung Transplantation</i> , <b>2020</b> , 39, 1435-1444	1	20
127	Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. <i>Respiratory Medicine</i> , <b>2020</b> , 177, 106241	4.4	3
126	Clinical Impact of Right Ventricular Diastolic Patterns in Idiopathic Pulmonary Arterial Hypertension by Speckle Tracking. <i>Journal of Heart and Lung Transplantation</i> , <b>2019</b> , 38, S487	1	
125	Clinical Implications of Idiopathic Pulmonary Arterial Hypertension Phenotypes Defined by Cluster Analysis. <i>Journal of Heart and Lung Transplantation</i> , <b>2019</b> , 38, S488	1	
124	Suppressor of Tumorigenicity 2 as a Biomarker in Pulmonary Arterial Hypertension and its Association with REVEAL Risk Score in Riociguat-Treated Patients in the RESPITE Study. <i>Journal of Heart and Lung Transplantation</i> , <b>2019</b> , 38, S96	1	
123	Exercise energy expenditure in patients with idiopathic pulmonary arterial hypertension: Impact on clinical severity and survival. <i>Respiratory Physiology and Neurobiology</i> , <b>2019</b> , 264, 33-39	2.7	1
122	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). <i>European Respiratory Journal</i> , <b>2019</b> , 54,	13.1	379
121	The added value of cardiopulmonary exercise testing in the follow-up of pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , <b>2019</b> , 38, 306-314	1	12

120	EXPRESS: Long term study of oral treprostinil to treat pulmonary arterial hypertension: dosing, tolerability, and pharmacokinetics. <i>Pulmonary Circulation</i> , <b>2019</b> , 2045894019866335	2.6	
119	Echocardiography Predicts the Outcome in Pulmonary Arterial Hypertension Patients Treated With Parenteral Prostanoids. <i>Journal of Heart and Lung Transplantation</i> , <b>2018</b> , 37, S206	1	
118	The impact of delayed treatment on 6-minute walk distance test in patients with pulmonary arterial hypertension: A meta-analysis. <i>International Journal of Cardiology</i> , <b>2018</b> , 254, 299-301	3	7
117	Initial tadalafil and ambrisentan combination therapy in pulmonary arterial hypertension: clinical and haemodynamic long-term efficacy (ITALY study). <i>Journal of Cardiovascular Medicine</i> , <b>2018</b> , 19, 12-17	1.8	15
116	Initial combination therapy for patients with pulmonary arterial hypertension (PAH): a budget impact analysis from the perspective of the Italian national healthcare system. <i>Expert Opinion on Orphan Drugs</i> , <b>2018</b> , 6, 1-7	1	
115	Influence of various therapeutic strategies on right ventricular morphology, function and hemodynamics in pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , <b>2018</b> , 37, 365-375	1	26
114	Haemodynamic effects of an acute vasodilator challenge in heart failure patients with reduced ejection fraction and different forms of post-capillary pulmonary hypertension. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 725-734	12	17
113	Switching from PDE5i to Riociguat in the RESPITE Study: Effect on Right Heart Function. <i>Journal of Heart and Lung Transplantation</i> , <b>2018</b> , 37, S152	1	1
112	The importance of right ventricular function in patients with pulmonary arterial hypertension. <i>Expert Review of Respiratory Medicine</i> , <b>2018</b> , 12, 809-815	3.6	1
111	Prognostic significance of the echocardiographic estimate of pulmonary hypertension and of right ventricular dysfunction in acute decompensated heart failure. A pilot study in HFrEF patients. <i>International Journal of Cardiology</i> , <b>2018</b> , 271, 301-305	3	5
110	Prognostic relevance of right heart reverse remodeling in idiopathic pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , <b>2017</b> ,	1	22
109	Efficacy of 1, 5, and 20 mg oral sildenafil in the treatment of adults with pulmonary arterial hypertension: a randomized, double-blind study with open-label extension. <i>BMC Pulmonary Medicine</i> , <b>2017</b> , 17, 44	3.3	9
108	Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 422-426	2.3	71
107	Right ventricular dyssynchrony and exercise capacity in idiopathic pulmonary arterial hypertension. <i>European Respiratory Journal</i> , <b>2017</b> , 49,	13.1	26
106	Incremental Benefit of Cardiopulmonary Exercise Testing for the Prediction of Outcome in Stable Prevalent Pulmonary Arterial Hypertension Patients. <i>Journal of Heart and Lung Transplantation</i> , <b>2017</b> , 36, S76	1	
105	Letter to the editor about the paper "Right ventricular dyssynchrony predicts clinical outcomes in patients with pulmonary hypertension" by Murata et al. <i>International Journal of Cardiology</i> , <b>2017</b> , 234, 128	3	1
104	Optimal duration of dual anti-platelet therapy after percutaneous coronary intervention: 2016 consensus position of the Italian Society of Cardiology. <i>Journal of Cardiovascular Medicine</i> , <b>2017</b> , 18, 1-9	1.8	3
103	RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. <i>European Respiratory Journal</i> , <b>2017</b> , 50,	13.1	65

102	Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial. <i>Journal of Heart and Lung Transplantation</i> , <b>2017</b> , 36, 166-174	1	56
101	Prognostic relevance of pulmonary arterial compliance after therapy initiation or escalation in patients with pulmonary arterial hypertension. <i>International Journal of Cardiology</i> , <b>2017</b> , 230, 53-58	3	22
100	Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. <i>European Respiratory Journal</i> , <b>2017</b> , 50,	13.1	273
99	An official European Respiratory Society statement: pulmonary haemodynamics during exercise. <i>European Respiratory Journal</i> , <b>2017</b> , 50,	13.1	116
98	Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial. <i>BMC Cardiovascular Disorders</i> , <b>2017</b> , 17, 239	2.2	19
97	Preoperative Evaluation of Patients Undergoing Lung Resection Surgery: Defining the Role of the Anesthesiologist on a Multidisciplinary Team. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , <b>2016</b> , 30, 530-8	1.8	20
96	Effects of Riociguat in Treatment-Naive vs Pretreated Patients With Pulmonary Arterial Hypertension: 2-Year Efficacy Results From the PATENT-2 Study. <i>Chest</i> , <b>2016</b> , 150, 1162A	1.2	1
95	Right Ventricular Dyssynchrony and Exercise Capacity in Idiopathic Pulmonary Arterial Hypertension: Insights Form Echocardiography and Cardiopulmonary Exercise Test. <i>Journal of Heart and Lung Transplantation</i> , <b>2016</b> , 35, S149	1	
94	Incremental Benefit of Echocardiographic Imaging and Cardiopulmonary Exercise Test in Prognostic Evaluation of Idiopathic Pulmonary Arterial Hypertension. <i>Journal of Heart and Lung Transplantation</i> , <b>2016</b> , 35, S149	1	
93	Right ventricular concentric hypertrophy and clinical worsening in idiopathic pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , <b>2016</b> , 35, 1321-1329	1	19
92	Echocardiography Combined With Cardiopulmonary Exercise Testing for the Prediction of Outcome in Idiopathic Pulmonary Arterial Hypertension. <i>Chest</i> , <b>2016</b> , 150, 1313-1322	1.2	30
91	Pre-Capillary, Combined, and Post-Capillary Pulmonary Hypertension: A Pathophysiological Continuum. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 368-78	4.6	144
90	Concentric Hypertrophy Protects Against Clinical Worsening in Idiopathic Pulmonary Arterial Hypertension: Insights From Magnetic Resonance Imaging. <i>Journal of Heart and Lung Transplantation</i> , <b>2015</b> , 34, S117	1	
89	Determinats and Prognostic Significance of Right Ventricular Reverse Remodeling in Idiopathic Pulmonary Arterial Hypertension Receiving Specific Medical Treatment. <i>Journal of Heart and Lung Transplantation</i> , <b>2015</b> , 34, S116-S117	1	
88	Muscular Efficiency in Patients With Idiopathic Pulmonary Arterial Hypertension (iPAH): Impact on Clinical Severity and Survival. <i>Journal of Heart and Lung Transplantation</i> , <b>2015</b> , 34, S339	1	
87	Heart failure in patients with human immunodeficiency virus: a review of the literature. <i>Journal of Cardiovascular Medicine</i> , <b>2015</b> , 16, 383-9	1.8	13
86	Right ventricular remodeling in idiopathic pulmonary arterial hypertension: adaptive versus maladaptive morphology. <i>Journal of Heart and Lung Transplantation</i> , <b>2015</b> , 34, 395-403	1	39
85	Ambrisentan for the treatment of adults with pulmonary arterial hypertension: a review. <i>Current Medical Research and Opinion</i> , <b>2015</b> , 31, 1793-807	2.4	12

84	Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 834-44	56.8	588
83	Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial Pneumonias. <i>PLoS ONE</i> , <b>2015</b> , 10, e0141911	3.6	48
82	Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , <b>2015</b> , 34, 1366-75	1	67
81	Right ventricular dyssynchrony in idiopathic pulmonary arterial hypertension: determinants and impact on pump function. <i>Journal of Heart and Lung Transplantation</i> , <b>2015</b> , 34, 381-9	1	39
80	Circulating biomarkers in pulmonary arterial hypertension: update and future direction. <i>Journal of Heart and Lung Transplantation</i> , <b>2015</b> , 34, 282-305	1	34
79	Right heart and pulmonary vessels structure and function. <i>Echocardiography</i> , <b>2015</b> , 32 Suppl 1, S3-10	1.4	18
78	Right Intraventricular Dyssynchrony in Idiopathic, Heritable, and Anorexigen-Induced Pulmonary Arterial Hypertension: Clinical Impact and Reversibility. <i>JACC: Cardiovascular Imaging</i> , <b>2015</b> , 8, 642-52	8	60
77	Pulmonary hypertension due to lung disease [Results from COMPERA <b>2015</b> ,		1
76	FRI0445 Efficacy and Safety of Riociguat in Patients with Pulmonary Arterial Hypertension (PAH) Associated with Connective Tissue Disease (CTD): Results from Patent-1 and Patent-2. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 588.2-589	2.3	1
75	Riociguat in Combination With Prostacyclin Analogs for the Treatment of Pulmonary Arterial Hypertension (PAH): A Subgroup Analysis of the PATENT Studies. <i>Chest</i> , <b>2015</b> , 148, 922A	1.2	2
74	Elevated serum levels of macrophage migration inhibitory factor and stem cell growth factor [n patients with idiopathic and systemic sclerosis associated pulmonary arterial hypertension. <i>Reumatismo</i> , <b>2015</b> , 66, 270-6	1	10
73	Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). <i>Circulation</i> , <b>2014</b> , 129, 57-65	16.2	223
72	Real-life Information on pulmonary arterial hypertension: the iPHnet Project. <i>Current Medical Research and Opinion</i> , <b>2014</b> , 30, 2409-14	2.4	4
71	Myocardial and microvascular inflammation/infection in patients with HIV-associated pulmonary artery hypertension. <i>Aids</i> , <b>2014</b> , 28, 2541-9	3.4	14
70	Changes in right ventricular function measured by cardiac magnetic resonance imaging in patients receiving pulmonary arterial hypertension-targeted therapy: the EURO-MR study. <i>Circulation: Cardiovascular Imaging</i> , <b>2014</b> , 7, 107-14	3.7	108
69	Right Ventricular Dyssynchrony in Idiopathic Pulmonary Arterial Hypertension: Insights From Echocardiographic and Cardiac Magnetic Resonance Imaging. <i>Journal of Heart and Lung Transplantation</i> , <b>2014</b> , 33, S229	1	
68	Right Ventricular Remodeling in Idiopathic Pulmonary Arterial Hypertension: Concentric Versus Eccentric Hypertrophy. <i>Journal of Heart and Lung Transplantation</i> , <b>2014</b> , 33, S148	1	1
67	SPHERIC-1 (Sildenafil and Pulmonary Hypertension in COPD): Intention-to-Treat (ITT) Analysis of Safety and Efficacy Data. <i>Journal of Heart and Lung Transplantation</i> , <b>2014</b> , 33, S148-S149	1	1

66	Demographics, clinical characteristics, health resource utilization and cost of chronic thromboembolic pulmonary hypertension patients: retrospective results from six European countries. <i>BMC Health Services Research</i> , <b>2014</b> , 14, 246	2.8	11
65	Response to letters regarding article, "Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)". <i>Circulation</i> , <b>2014</b> , 130, e110-2	16.2	4
64	Choosing the best first line oral drug agent in patients with pulmonary hypertension: evidence from a network meta-analysis. <i>International Journal of Cardiology</i> , <b>2013</b> , 168, 4336-8	3	4
63	Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. <i>International Journal of Cardiology</i> , <b>2013</b> , 168, 871-80	3	227
62	Relationship between baseline ET-1 plasma levels and outcome in patients with idiopathic pulmonary hypertension treated with bosentan. <i>International Journal of Cardiology</i> , <b>2013</b> , 167, 220-4	3	9
61	Therapy for pulmonary arterial hypertension due to congenital heart disease and Down's syndrome. <i>International Journal of Cardiology</i> , <b>2013</b> , 164, 323-6	3	45
60	Mode of Death in Patients with Pulmonary Arterial Hypertension. <i>Journal of Heart and Lung Transplantation</i> , <b>2013</b> , 32, S17-S18	1	
59	Myocardial and micro-vascular inflammation/infection in HIV/HCV associated pulmonary artery hypertension. <i>European Heart Journal</i> , <b>2013</b> , 34, P228-P228	9	
58	Systemic sclerosis patients with and without pulmonary arterial hypertension: a nailfold capillaroscopy study. <i>Rheumatology</i> , <b>2013</b> , 52, 1525-8	3.8	49
57	Riociguat for the treatment of pulmonary arterial hypertension. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 330-40	56.8	830
56	Macitentan and morbidity and mortality in pulmonary arterial hypertension. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 809-18	56.8	840
55	Right Ventricular Dyssynchrony Predicts Clinical Worsening in Idiopathic Pulmonary Arterial Hypertension. <i>Journal of Heart and Lung Transplantation</i> , <b>2013</b> , 32, S79	1	
54	Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey. <i>European Respiratory Journal</i> , <b>2013</b> , 41, 1302-7	13.1	86
53	Pulmonary hypertension in systemic sclerosis: prevalence, incidence and predictive factors in a large multicentric Italian cohort. <i>Clinical and Experimental Rheumatology</i> , <b>2013</b> , 31, 31-6	2.1	22
52	Pulmonalerterielle Hypertonie bei angeborenen Herzfehlern: Problemstellung und Versorgungslage. <i>Deutsche Medizinische Wochenschrift</i> , <b>2013</b> , 138, e27-e27	0	
51	PCV22 Treatment Patterns and Outcomes in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Results of a Retrospective Chart Review in Six European Countries. <i>Value in Health</i> , <b>2012</b> , 15, A115	0.3	
50	Analysis of endothelin-1 and endothelin-1 receptor A gene polymorphisms in patients with pulmonary arterial hypertension. <i>Internal and Emergency Medicine</i> , <b>2012</b> , 7, 425-30	3.5	19
49	Pregnancy outcomes in pulmonary arterial hypertension in the modern management era. <i>European Respiratory Journal</i> , <b>2012</b> , 40, 881-5	13.1	156

48	Safety and efficacy evaluation of ambrisentan in pulmonary hypertension. <i>Expert Opinion on Drug Safety</i> , <b>2012</b> , 11, 1003-11	3.9	16
47	Chronic Inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging. <i>Circulation</i> , <b>2012</b> , 125, 2323-33	16.2	128
46	Pulmonary arterial dilatation in pulmonary hypertension: prevalence and prognostic relevance. <i>Cardiology</i> , <b>2012</b> , 121, 76-82	1.5	24
45	Prognostic factors in severe pulmonary hypertension patients who need parenteral prostanoid therapy: the impact of late referral. <i>Journal of Heart and Lung Transplantation</i> , <b>2012</b> , 31, 364-72	1	33
44	Unusual presentation for a patent ductus arteriosus. <i>European Respiratory Review</i> , <b>2009</b> , 18, 174-6	9.3	
43	258: Predictors of Clinical Worsening in Patients with PAH Treated with Bosentan. <i>Journal of Heart and Lung Transplantation</i> , <b>2009</b> , 28, S156-S157	1	
42	Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study. <i>Journal of Clinical Pharmacology</i> , <b>2009</b> , 49, 1343-52	2.7	47
41	Pathophysiological adaptations to walking and cycling in primary pulmonary hypertension. <i>European Journal of Applied Physiology</i> , <b>2008</b> , 102, 417-24	3.2	26
40	Venous endothelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension. <i>Regulatory Peptides</i> , <b>2008</b> , 151, 48-53		13
39	Usefulness of tricuspid annular velocity in identifying global RV dysfunction in patients with primary pulmonary hypertension: a comparison with 3D echo-derived right ventricular ejection fraction. <i>Echocardiography</i> , <b>2008</b> , 25, 289-93	1.4	27
38	Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect. <i>Heart</i> , <b>2007</b> , 93, 621-5	4.9	62
37	ACUTE HEMODYNAMIC EFFECT OF SILDENAFIL IN COMPARISON WITH INHALED NITRIC OXIDE IN PATIENTS RECEIVING BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION. <i>Chest</i> , <b>2007</b> , 132, 488A	1.2	
36	Treatment of pulmonary hypertension in patients undergoing cardiac surgery with cardiopulmonary bypass: a randomized, prospective, double-blind study. <i>Journal of Cardiovascular Medicine</i> , <b>2006</b> , 7, 119-23	1.8	49
35	Effects of glucose-insulin-potassium infusion on myocardial perfusion and left ventricular remodeling in patients treated with primary angioplasty for ST-elevation acute myocardial infarction. <i>American Journal of Cardiology</i> , <b>2006</b> , 98, 1349-53	2.9	21
34	Mid-term efficacy of beraprost, an oral prostacyclin analog, in the treatment of distal CTEPH: a case control study. <i>Cardiology</i> , <b>2006</b> , 106, 168-73	1.5	13
33	Plasma adrenomedullin and endothelin-1 concentration during low-dose dobutamine infusion: Relationship between pulmonary uptake and pulmonary vascular pressure/flow characteristics. <i>Regulatory Peptides</i> , <b>2006</b> , 136, 85-91		1
32	Tissue viability by contrast echocardiography. <i>European Journal of Echocardiography</i> , <b>2006</b> , 7, S22-S29		1
31	BOSENTAN THERAPY IN PATIENTS WITH PULMONARY HYPERTENSION SECONDARY TO CONGENITAL HEART DISEASE (EISENMENGER PHYSIOLOGY). <i>Chest</i> , <b>2005</b> , 128, 366S	1.2	



30	Increased plasma levels of adrenomedullin, a vasoactive peptide, in patients with end-stage pulmonary disease. <i>Regulatory Peptides</i> , <b>2005</b> , 124, 187-93		20
29	Human herpesvirus 8 and pulmonary hypertension. <i>Emerging Infectious Diseases</i> , <b>2005</b> , 11, 1480-2	9.9	10
28	Human Herpesvirus 8 and Pulmonary Hypertension. <i>Emerging Infectious Diseases</i> , <b>2005</b> , 11, 1480-1482	9.9	28
27	Human Herpesvirus 8 and Pulmonary Hypertension. <i>Emerging Infectious Diseases</i> , <b>2005</b> , 12, 1480-1482	9.9	
26	BASELINE VENOUS ENDOTHELIN-1 (ET1) PLASMA LEVELS DOES NOT PREDICT CLINICAL RESPONSE TO BOSENTAN IN PULMONARY ARTERIAL HYPERTENSION. <i>Chest</i> , <b>2005</b> , 128, 202S	1.2	
25	HIV-related pulmonary hypertension. From pathogenesis to clinical aspects. <i>Acta Cardiologica</i> , <b>2004</b> , 59, 323-30	0.9	21
24	Prostanoid therapy for pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , <b>2004</b> , 43, 56S-61S	4.6	147
23	Comparative effects of irbesartan versus amlodipine on left ventricular mass index in hypertensive patients with left ventricular hypertrophy. <i>Journal of Cardiovascular Pharmacology</i> , <b>2003</b> , 42, 622-8	3	33
22	Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. <i>Journal of the American College of Cardiology</i> , <b>2002</b> , 39, 1496-502	4.6	465
21	Usefulness of 2D echo Doppler in the preoperative assessment of cystic fibrosis patients who are candidates for lung transplantation. <i>Transplantation Proceedings</i> , <b>2001</b> , 33, 1628-9	1.1	2
20	Improved results with lung transplantation for cystic fibrosis. <i>Transplantation Proceedings</i> , <b>2001</b> , 33, 1632-3		7
19	Inhaled aerosolized prostacyclin and pulmonary hypertension during anesthesia for lung transplantation. <i>Transplantation Proceedings</i> , <b>2001</b> , 33, 1634-6	1.1	22
18	Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue. <i>British Heart Journal</i> , <b>2001</b> , 86, 661-5		36
17	Acute hemodynamic effects of inhaled nitric oxide, dobutamine and a combination of the two in patients with mild to moderate secondary pulmonary hypertension. <i>Critical Care</i> , <b>2001</b> , 5, 355-61	10.5	59
16	Pulmonary hemodynamics contribute to indicate priority for lung transplantation in patients with cystic fibrosis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2000</b> , 119, 682-9	1.4	45
15	Outcome of patients with cystic fibrosis awaiting lung transplantation. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2000</b> , 162, 819-25	9.6	77
14	Locoregional versus general anesthesia in carotid surgery: is there an impact on perioperative myocardial ischemia? Results of a prospective monocentric randomized trial. <i>Journal of Vascular Surgery</i> , <b>1999</b> , 30, 131-8	1.5	65
13	Tissue-type plasminogen activator therapy versus primary coronary angioplasty: impact on myocardial tissue perfusion and regional function 1 month after uncomplicated myocardial infarction. <i>Journal of the American College of Cardiology</i> , <b>1998</b> , 31, 338-43	4.6	32

12	Timing and priorities for cystic fibrosis patients candidates to lung transplantation. <i>European Journal of Pediatric Surgery</i> , <b>1998</b> , 8, 274-7	1.8	14
11	Right and left ventricular dysfunction in patients with severe pulmonary disease. <i>Chest</i> , <b>1998</b> , 113, 576-83	2	232
10	Clinical impact of echocardiography in prognostic stratification after acute myocardial infarction. <i>American Journal of Cardiology</i> , <b>1998</b> , 81, 17G-20G	2.9	10
9	Occult lung cancer in patients with bullous emphysema. <i>Thorax</i> , <b>1997</b> , 52, 289-90	7	17
8	Efficacy of Amlodipine in the Treatment of Stable Effort Angina. <i>Clinical Drug Investigation</i> , <b>1997</b> , 13, 108-112	3.1	
7	Hemodynamics during inhaled nitric oxide in lung transplant candidates. <i>Transplantation Proceedings</i> , <b>1997</b> , 29, 3367-70	1.1	9
6	Reconstruction of the pulmonary artery by a conduit of autologous pericardium. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>1995</b> , 110, 867-8	1.4	29
5	Transesophageal dipyridamole echocardiography for diagnosis of coronary artery disease. <i>Journal of the American College of Cardiology</i> , <b>1992</b> , 19, 765-70	4.6	54
4	Endogenous opioid system modulation in anginal pain: demonstration of its central activity. <i>American Heart Journal</i> , <b>1992</b> , 124, 589-95	4.7	4
3	Identification of coronary artery by-pass grafts: reliability of MRI in clinical practice. <i>International Journal of Cardiovascular Imaging</i> , <b>1992</b> , 8, 85-94		4
2	Assessment of severity of coronary narrowings by quantitative exercise echocardiography and comparison with quantitative arteriography. <i>American Journal of Cardiology</i> , <b>1991</b> , 67, 1201-7	2.9	38
1	Usefulness of the dipyridamole-Doppler test for diagnosis of coronary artery disease. <i>American Journal of Cardiology</i> , <b>1990</b> , 65, 829-34	2.9	28